• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Low starting-dosage of nintedanib for the reduction of early termination.

作者信息

Ikeda Satoshi, Sekine Akimasa, Baba Tomohisa, Katano Takuma, Tabata Erina, Shintani Ryota, Yamakawa Hideaki, Niwa Takashi, Oda Tsuneyuki, Okuda Ryo, Kitamura Hideya, Ogura Takashi

机构信息

Kanagawa Cardiovascular and Respiratory Center, Department of Respiratory Medicine, Tomioka-Higashi 6-16-1, Kanazawa-ku, Yokohama 236-0051, Japan.

出版信息

Respir Investig. 2019 May;57(3):282-285. doi: 10.1016/j.resinv.2018.12.010. Epub 2019 Feb 13.

DOI:10.1016/j.resinv.2018.12.010
PMID:30772264
Abstract
摘要

相似文献

1
Low starting-dosage of nintedanib for the reduction of early termination.用于减少提前终止的低起始剂量的尼达尼布。
Respir Investig. 2019 May;57(3):282-285. doi: 10.1016/j.resinv.2018.12.010. Epub 2019 Feb 13.
2
Tolerability and safety of nintedanib in elderly patients with idiopathic pulmonary fibrosis.尼达尼布治疗特发性肺纤维化老年患者的耐受性和安全性。
Respir Investig. 2021 Jan;59(1):99-105. doi: 10.1016/j.resinv.2020.08.003. Epub 2020 Sep 3.
3
Safety and efficacy of nintedanib in idiopathic pulmonary fibrosis: A real-life observational study in Greece.尼达尼布治疗特发性肺纤维化的安全性和疗效：希腊的一项真实世界观察性研究。
Pulm Pharmacol Ther. 2018 Apr;49:61-66. doi: 10.1016/j.pupt.2018.01.006. Epub 2018 Jan 31.
4
Pulmonary Hypertension Exacerbated by Nintedanib Administration for Idiopathic Pulmonary Fibrosis.尼达尼布治疗特发性肺纤维化加重肺动脉高压
Intern Med. 2019 Apr 1;58(7):965-968. doi: 10.2169/internalmedicine.1384-18. Epub 2018 Dec 18.
5
Long-Term Effects and Adverse Events of Nintedanib Therapy in Idiopathic Pulmonary Fibrosis Patients with Functionally Advanced Disease.尼达尼布治疗有功能进展的特发性肺纤维化患者的长期疗效和不良事件。
Adv Ther. 2019 May;36(5):1221-1232. doi: 10.1007/s12325-019-00906-9. Epub 2019 Mar 14.
6
Anti-glomerular basement membrane glomerulonephritis following nintedanib for idiopathic pulmonary fibrosis: a case report.尼达尼布治疗特发性肺纤维化后发生的抗肾小球基底膜肾小球肾炎：一例报告
J Med Case Rep. 2017 Aug 6;11(1):214. doi: 10.1186/s13256-017-1384-2.
7
First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value.关于尼达尼布治疗特发性肺纤维化且用力肺活量≤预测值50%患者的疗效和安全性的初步数据。
Lung. 2016 Oct;194(5):739-43. doi: 10.1007/s00408-016-9912-1. Epub 2016 Jul 4.
8
Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis.INPULSIS™试验的设计：两项尼达尼布治疗特发性肺纤维化患者的3期试验。
Respir Med. 2014 Jul;108(7):1023-30. doi: 10.1016/j.rmed.2014.04.011. Epub 2014 Apr 29.
9
Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis.尼达尼布联合吡非尼酮治疗特发性肺纤维化的安全性。
Eur Respir J. 2018 Aug 2;52(2). doi: 10.1183/13993003.00230-2018. Print 2018 Aug.
10
Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis.尼达尼布治疗特发性肺纤维化患者时用力肺活量的稳定性或改善。
Eur Respir J. 2018 Aug 2;52(2). doi: 10.1183/13993003.02593-2017. Print 2018 Aug.

引用本文的文献

1
Clinical significance of high monocyte counts for the continuous treatment with nintedanib.高单核细胞计数对尼达尼布持续治疗的临床意义。
BMC Pulm Med. 2023 Jul 3;23(1):242. doi: 10.1186/s12890-023-02536-y.
2
Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan.尼达尼布治疗特发性肺纤维化的真实世界安全性和耐受性：日本上市后监测的中期报告。
Adv Ther. 2023 Apr;40(4):1474-1493. doi: 10.1007/s12325-022-02411-y. Epub 2023 Jan 24.
3
Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.
特发性肺纤维化患者中吡非尼酮与尼达尼布之间的差异停药情况
Cells. 2022 Jan 2;11(1):143. doi: 10.3390/cells11010143.
4
Three cases of sequential treatment with nintedanib following pulsed-dose corticosteroids for acute exacerbation of interstitial lung diseases.三例间质性肺疾病急性加重期在脉冲剂量皮质类固醇治疗后序贯使用尼达尼布的病例。
Respir Med Case Rep. 2021 Mar 9;33:101385. doi: 10.1016/j.rmcr.2021.101385. eCollection 2021.